SCHEMBL6950446

SCHEMBL6950446

Cc1nc(OCCN2CCOCC2)c([N+](=O)[O-])c(N2CCc3ccccc3CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
KMT2A Q03164 3/20 0.56
MGMT P16455 2/20 0.49
MAPT P10636 5/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2D6 P10635 1/20 0.44
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 1/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 6/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HIF1A Q16665 1/20 0.41
MEN1 O00255 2/20 0.40
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6951003 0.84 MGMT (0.42) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6945292 0.84 MGMT (0.45) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6953559 0.84 MAPT (0.49) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6949472 0.83 MGMT (0.42) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6948575 0.83 MGMT (0.42) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6957503 0.83 MGMT (0.44) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6948483 0.82 HRH4 (0.41) SMN1; SMN2KMT2AMGMTMAPTKDM4E
SCHEMBL6955505 0.82 MGMT (0.47) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6947669 0.80 MGMT (0.40) SMN1; SMN2KMT2AMGMTMAPTCYP1A2
SCHEMBL6949320 0.80 MGMT (0.39) SMN1; SMN2KMT2AMGMTMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed